Global Eukaryotic Expression Systems Market, By Type (MEL, COS, CHO, Insect cells, Reagents, Expression Vectors, Competent Cells), Host Type (S.Cerevisiae, Filamentous Fungi, Leishamania, Baculovirus Infected Cells), Application (Bacterial Expression System, Yeast Expression System, Insect Expression System, Mammalian Expression System) – Industry Trends and Forecast to 2029.
Eukaryotic Expression Systems Market Analysis and Size
The ability of eukaryotic expression systems to perform numerous post-translational modifications has contributed to their growing popularity. Currently, there are three expression systems: yeast expression systems, insect cell expression systems, and mammalian cell expression systems. To drive the expression of a foreign gene, the methylotropic yeast Pichia Pastoris typically uses an alcohol oxidase promoter. The increasing trend of research activities in pharmaceutical companies will propel the market growth of eukaryotic expression systems.
Data Bridge Market Research analyses that the eukaryotic expression systems market which was USD 0.651 billion in 2021, is expected to reach USD 1 billion by 2029, at a CAGR of 5.50% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Eukaryotic Expression Systems Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (MEL, COS, CHO, Insect cells, Reagents, Expression Vectors, Competent Cells), Host Type (S.Cerevisiae, Filamentous Fungi, Leishamania, Baculovirus Infected Cells), Application (Bacterial Expression System, Yeast Expression System, Insect Expression System, Mammalian Expression System)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), QIAGEN (Germany), Promega Corporation (U.S.), Thermo Fischer Scientific, Inc. (U.S.), Takara Bio Inc. (Japan), GenScript (U.S.), Lonza (Switzerland), New England Biolabs (U.S.), Oxford Expression Technology (U.K.), LifeSensors Inc. (U.S.), Proteogenix (France), Synthetic Genomics Inc. (U.S.), Peak Proteins Ltd (U.K.), Sino Biological Inc. (China), ARTES Biotechnology GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
Expression systems are encoded by DNA to produce RNA and protein either inside or outside the cell wall. The eukaryotic expression system is an artificial system that involves drug development and the production of recombinant proteins, which are then used as research tools and therapeutics. For instance, MEL, COS, CHO, and insect cells are eukaryotic expression systems. Eukaryotic hosts are just as simple to manage as E.coli. They have stable expression strains that allow for consistent protein production.
Global Eukaryotic Expression Systems Market Dynamics
Drivers
- Rising use of E.coli bacteria
The market is expanding due to the large-scale production of a protein using E. coli bacteria, as E. coli is the most commonly used artificial expression host and is widely used because of its genomic and physiological sequencing system, which is responsible for simplifying the cloning procedure and making the E. coli host the most popular in the pharmaceutical industry. Furthermore, this process increases the binding strength of promoter region 7 and aiding in transcription. Furthermore, eukaryotic expression is critical in the pharmaceutical and biotechnology industries. These factors are expected to boost growth.
- Emerging trend of outsourcing R&D activities to CROs
The eukaryotic expression systems market is expected to be influenced by a drop in sales from future patient cliffs as well as a decline in research and development productivity. Furthermore, several pharmaceutical companies outsource their R&D programs to various contract research organizations (CROs). All of these factors are expected to support the growth of the eukaryotic expression systems market from 2020 to 2030.
Opportunities
- Technological development
Increasing advancement in genomic sequences along with technological advancement for instance, in April 2020, Bio-Rad laboratories, Inc., a leading life science research organization based in the United States, acquired Celsee, Inc. to provide instruments and consumables for the isolation, detection, and analysis of single cells.in proteomics which will further boost various opportunities for the growth of the eukaryotic expression systems market in the above mentioned forecast period.
Restraints/Challenges
- High cost of protein expression
High barriers on the new organization's entry and high cost of protein expression reagents will obstruct the market's growth rate. Limited disease awareness, high product costs, poor economic conditions, and a lack of favorable insurance systems all limit the adoption of eukaryotic expression systems products in developing regions around the world.
This eukaryotic expression systems market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the eukaryotic expression systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In April 2020, Bio-Rad Laboratories, Inc, a leading life science research firm based in the United States, acquired Celsee, Inc. The latter sells consumables and instruments for single cell analysis, detection, and isolation. This acquisition is expected to help Bio-Rad Laboratories achieve its goals of becoming a leader in the life science research sector and expanding its product portfolio.
Global Eukaryotic Expression Systems Market Scope
The eukaryotic expression systems market is segmented on the basis of type, host type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- MEL
- COS
- CHO
- Insect cells
- Reagents
- Expression Vectors
- Competent Cells
Host Type
- S.Cerevisiae
- Filamentous Fungi
- Leishamania
- Baculovirus Infected Cells
Application
- Bacterial Expression System
- Yeast Expression System
- Insect Expression System
- Mammalian Expression System
Eukaryotic Expression Systems Market Regional Analysis/Insights
The eukaryotic expression systems market is analyzed and market size insights and trends are provided by country, type, host type and application as referenced above.
The countries covered in the eukaryotic expression systems market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the eukaryotic expression systems market owing to factors such as continuous advancements in genome sequencing and innovations in proteomics in countries such as US and Canada.
Asia-Pacific will dominate during the forecast period of 2022 to 2029 due to the cumulative research studies conducted by market participants, as well as growing investment in research and development activities, are likely to motivate market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The eukaryotic expression systems market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for eukaryotic expression systems market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the eukaryotic expression systems market. The data is available for historic period 2010-2020.
Competitive Landscape and Eukaryotic Expression Systems Market Share Analysis
The eukaryotic expression systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to eukaryotic expression systems market.
Some of the major players operating in the eukaryotic expression systems market are:
- Agilent Technologies, Inc. (U.S.)
- Merck KGaA (Germany)
- Bio-Rad Laboratories, Inc. (U.S.)
- QIAGEN (Germany)
- Promega Corporation (U.S.)
- Thermo Fischer Scientific, Inc. (U.S.)
- Takara Bio Inc. (Japan)
- GenScript (U.S.)
- New England Biolabs (U.S.)
- Oxford Expression Technology (U.K.)
- LifeSensors Inc. (U.S.)
- Lonza (Switzerland)
- Proteogenix (France)
- Synthetic Genomics Inc. (U.S.)
- Peak Proteins Ltd (U.K.)
- Sino Biological Inc. (China)
- ARTES Biotechnology GmbH (Germany)
SKU-